LQDA
Liquidia Corporation
Drug Manufacturers - Specialty & Generic · Healthcare · United States
44.99
close · 2026-10-29
value
2
cheaper than peers2
quality
94
stronger fundamentals94
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 20.57× | 20 |
| price to book | 20.54× | 16 |
| EV to EBITDA | 167.12× | 2 |
| price to sales | 24.32× | 1 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 4158.5% | 99 |
| operating margin | 46.3% | 94 |
| return on equity | 28.2% | 87 |
| debt to equity | 170.2% | 27 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | $9.6M |
| employees | 216 |
| first trade | 2018-07-26 |
| next earnings | 2026-08-12 |
| fundamentals updated | 2026-08-12 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.80 | -1.66 | -1.21 | -0.67 |
| free cash flow | -$42.0M | -$101.9M | -$52.9M | -$29.2M |
| net income | -$68.9M | -$128.3M | -$78.5M | -$41.0M |
| revenue | $158.3M | $14.0M | $17.5M | $15.9M |
| unusual items | $0 | $0 | -$2.3M | -$997,000 |